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Introduction: TheSpanish inﬂuenza surveillance system(SISS)maintained its activity during the summer
of 2009 to monitor the inﬂuenza pandemic.
Objectives: To describe pandemic inﬂuenza activity from May to September 2009 and to estimate the
effectiveness of the 2008-9 seasonal inﬂuenza vaccine against laboratory-conﬁrmed pandemic (H1N1)
2009 inﬂuenza.
Methods: Data from the SISS were used to identify the trend of pandemic (H1N1) 2009 inﬂuenza outside
the inﬂuenza season. For the effectiveness study, we compared the vaccination status of notiﬁed cases
[inﬂuenza-like illnesses (ILI) laboratory conﬁrmed as pandemic inﬂuenza] with that of the test-negative
controls.
Results: The ﬁrst laboratory-conﬁrmed case of the pandemic virus was notiﬁed in the system in week
20/2009. The ILI rate increased gradually in the study period, exceeding basic activity in week 38. The
proportion of pandemic (H1N1) 2009 inﬂuenza viruses detected by the system represented 14% in week
20/2009 and rapidly increased to 90% in week 34. The adjusted vaccine effectiveness of the 2008-9
seasonal vaccine against laboratory-conﬁrmed pandemic inﬂuenza was 12% (-30; 41).
Conclusions: The SISS became an essential tool for pandemicmonitoring in Spain. The improved SISSwill
provide more accurate information on inﬂuenza activity in future seasonal or pandemic waves. Using
surveillance data, we could not demonstrate the effectiveness of the seasonal 2008-9 vaccine against
laboratory-conﬁrmed pandemic inﬂuenza.
© 2010 SESPAS. Published by Elsevier España, S.L. All rights reserved.
Actividad de la gripe pandémica (H1N1) 2009 durante el verano de 2009. Efec-
tividad de la vacuna trivalente 2008-9 frente a la gripe pandémica en Espan˜a
alabras clave:
ripe humana
igilancia centinela
acuna antigripal
fectividad vacunal
r e s u m e n
Introducción: El Sistema de Vigilancia de Gripe en Espan˜a (SVGE) continuó y reforzó su actividad durante
el verano de 2009 con el objetivo de vigilar la evolución de la pandemia en Espan˜a.
Objetivos: Describir la actividad de la gripe pandémica en Espan˜a de mayo a septiembre de 2009 y
estimar la efectividad de la vacuna antigripal estacional 2008-2009 frente a casos conﬁrmados de gripe
pandémica (H1N1) 2009.
Métodos: Se utilizaron datos del SVGE para presentar la evolución de la pandemia por virus (H1N1) 2009
fuera de la temporada de vigilancia 2008-2009. Para el estudio de la efectividad vacunal se comparó el
estado vacunal de los casos de gripe pandémica conﬁrmados por laboratorio con el de los casos negativos
para el virus de la gripe (controles negativos).
Resultados: Elprimer caso conﬁrmadodeviruspandémico senotiﬁcóen la semana20/2009. La incidencia
de gripe aumentó paulatinamente durante el periodo estudiado y sobrepasó el umbral basal en la semana
38/2009. Laproporcióndevirus (H1N1)2009detectadaporel SVGE fuedel 14%en la semana20yaumentó
rápidamente, llegando a alcanzar el 90% en la semana 34. La efectividad ajustada de la vacuna antigripal
2008-2009 frente a casos conﬁrmados de gripe pandémica fue del 12% (-30; 41).
adapConclusiones: El SVGE se
de vigilancia de la pandemia. E
epidémicas/pandémicas. Con l
de la vacuna antigripal 2008-2
© 2010 S
∗ Corresponding author.
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♦ Appendix A contains the list of the researchers and institutions participants in the Sp
213-9111/$ – see front matter © 2010 SESPAS. Published by Elsevier España, S.L. All righ
oi:10.1016/j.gaceta.2010.06.010tó y mejoró de forma rápida a las exigencias nacionales e internacionales
sta mejora supone información más precisa y de calidad en futuras ondas
os datos obtenidos en vigilancia no se pudo demostrar alguna efectividad
009 frente a los casos de gripe pandémica conﬁrmados por laboratorio.
ESPAS. Publicado por Elsevier España, S.L. Todos los derechos reservados.
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On 27 April 2009, Spain reported the ﬁrst case of the inﬂuenza
andemic (H1N1) 2009 infection in Europe.1 Since then, the
nﬂuenza surveillance strategy was adapted to the pandemic
rogress, according to the recommendations of the Spanish pan-
emic preparedness plan for the containment and mitigation
hases.2,3 FollowingWHOalert ofpandemicphase5,4 theEuropean
entre for Disease Prevention and Control (ECDC) recommended
o the European Union Member States to continue the inﬂuenza
urveillance within the inﬂuenza surveillance sentinel systems.5
fter pandemic phase 6 declaration,6 a gradual transition from
ase-based reporting to sentinel surveillance and surveillance of
evere cases was implemented in Spain.3
The Spanish Inﬂuenza Surveillance System (SISS) was estab-
ished in 19967 and since then it was integrated in European
nﬂuenza Surveillance Network (former European Inﬂuenza
urveillance Scheme).8 The objectives of the surveillance system
re to provide timely epidemiological and virological information
n inﬂuenzaactivity inSpain fromweek40ofoneyear toweek20of
he following year. In line with ECDC recommendation, SISS main-
ained its activity during the summer 2009, from week 20/2009 to
eek 39/2009. The sixteen Spanish regional sentinel networks and
egional laboratories integrated in the surveillance system were
ecommended to:1) increase thenumberof sentinel general practi-
ioners (GPs) and paediatricians (PDs) participating in the network;
) swab all patients meeting the inﬂuenza case deﬁnition and con-
ulting a sentinel GP; and 3) train sentinel GPs and PDs for adopting
he inﬂuenza European Commission case deﬁnition.9
Inﬂuenza vaccine effectiveness of the trivalent seasonal vaccine
gainst the pandemic (H1N1) 2009 virus has been estimated in
ther countries10–12 using different designs. The routine surveil-
ance system was used in Australia to estimate the effectiveness
f trivalent vaccine during the inﬂuenza season in the Southern
emisphere, comparing the vaccination status of the laboratory
onﬁrmed cases with that of the test-negative controls.10 The test-
egative design was previously used to estimate trivalent seasonal
nﬂuenza effectiveness13,14 and pilot tested using the SISS15–17 as
art of the ECDC funded I-MOVE project.18
The aimof this paper is to describe the epidemiological and viro-
ogical activity of the inﬂuenza pandemic (H1N1) 2009 in Spain,
rom May to September 2009, using the information obtained from
he inﬂuenza surveillance. We also aimed at measuring the effec-
iveness of the trivalent seasonal vaccine 2008-9 against medically
ttended laboratory conﬁrmed pandemic inﬂuenza (H1N1) 2009 in
rder to guide public health recommendations.
ethods
escription of Spanish Inﬂuenza Surveillance System
The Spanish inﬂuenza surveillance system comprises networks
f sentinel physicians and network-afﬁliated laboratories, includ-
ng the National Inﬂuenza Centre-Madrid (NIC-Madrid, WHO
ational Inﬂuenza Centre, National Centre of Microbiology). In
ddition to the specimens taken by sentinel physicians, regional
aboratories also collect specimens from non-sentinel sources (i.e.
ospitals, collaborating laboratories). Inﬂuenza detections from
on-sentinel sources are notiﬁed to the system. In the season
008-9, SISS included over 524 GPs and 173 PDs from 16 Span-
sh Autonomous Communities (ACs). The system covered 926,092
nhabitants, representing 2.07% of the total population of the 16
Cs. GPs and PDs report on weekly basis cases of inﬂuenza like
llness (ILI) detected in their reference populations. In the 2008-
season, 12 Spanish sentinel networks used the ILI deﬁnition of. 2011;25(1):23–28
International Classiﬁcation of Health Problems in Primary Care19:
1) context of inﬂuenza epidemic and four of the criteria listed in the
point 2; or 2) six of the following criteria: onset within 12hours,
cough, fever, chills, prostration and weakness, myalgia or general
pain, rhinitis, pharyngitis, contact with a case. Four Spanish sen-
tinel networks used an ILI deﬁnition based on the European case
deﬁnition9: sudden onset of symptoms, and at least one out of
four systemic symptoms: fever or feverishness, malaise, headache,
myalgia; and at least one out of three respiratory symptoms: cough,
sore throat, shortness of breath; and in the absence of other sus-
pected clinical diagnosis.
For virological inﬂuenza surveillance, sentinel physicians took
nasal or nasopharyngeal swabs, and sent them for inﬂuenza virus
detection to the regional laboratories and network afﬁliated labo-
ratories in each Autonomous Communities. Starting the inﬂuenza
enhanced surveillance, all patients meeting the ILI case deﬁnition
were swabbed. The swabbing strategy changed along the surveil-
lance period, from all cases to a systematic swabbing, according
to network resources and laboratory capacity. If the assay to con-
ﬁrm the inﬂuenza pandemic (H1N1) 2009 viruswas not available at
the regional laboratories, specimens were sent to the the National
Reference Laboratory. Two independent assays were used for
detection of pandemic inﬂuenza (H1N1) 2009 virus: 1) a multiplex
reverse transcription (RT)-nested PCR assay for generic detection
of Inﬂuenza A, B and C designed in the Nucleoprotein gene, and
2) a multiplex RT-nested PCR assay for sub-typing of the Haemag-
glutinin gene of inﬂuenza A viruses. Ampliﬁed products from both
RT-PCR assays were sequenced and identiﬁcation of (H1N1) 2009
viruswas performed after sequence analysis.20 Formolecular char-
acterizations of resistance to antivirals, analysis of Matrix and
Neuraminidase genes were also performed in all available isolates.
The data collected in the SISS included: sex, age, sentinel/non
sentinel source, date of symptoms onset, date of swabbing,
vaccination status, inﬂuenza laboratory conﬁrmation, inﬂuenza
type/subtype and inﬂuenza strain. Data was entered weekly, by
each regional sentinel network in a web-based application and
analysed at central level by the National Centre of Epidemiology, to
provide timely information on the evolution of inﬂuenza activity at
ACs and national level (http://vgripe.isciii.es/gripe).
Study of inﬂuenza vaccine 2008-9 effectiveness
Based on SISS data, we conducted a case-control study using
the laboratory results of swabs taken from week 20 to week 39
(May-September 2009). Cases were medically attended ILI, labora-
tory conﬁrmed for pandemic inﬂuenza (H1N1) 2009. Controlswere
medically attended ILI that tested negative for any inﬂuenza type
in a SISS-afﬁliated laboratory (test-negative controls).
The WHO recommended inﬂuenza triple vaccine for Northern
hemisphere in the 2008-9 season21 was the exposure for the effec-
tiveness study. Annual vaccination is recommended in Spain for the
high risk groups for inﬂuenza complications: patients with chronic
conditions at any age, health care workers, elderly over 65 years
old (over 60 years in some ACs).22 Vaccination is conducted at the
GP/PD level during the annual campaign that lasted from October
to December 2008, depending on Autonomous Community organi-
zation. Data on vaccination is collected by the GP/PD according to
the patient clinical history. We excluded from the analysis ILI cases
that had unknown vaccination status, no age nor laboratory results
reported in the system.For statistical analysis, we compared the characteristics of cases
and controls by sex and age using Pearson’s chi-square test. We
calculated the crude and adjusted odds ratios (OR), their corre-
sponding 95% conﬁdence intervals (95%CI) using logistic regression
and computed the vaccine effectiveness as (1-OR)*100. Variables
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fInfluenza positive specimens (2008-2009 season)
Enhanced surveillance. Weeks 20-39/2009 influenza rate per 100
Figure 1. Weekly inﬂuenza incidence rate and proportion of inﬂue
ncluded in the regression model were: age group, sex, month of
wabbing and Autonomous Community. We adjusted for month of
wabbing to control for differences in inﬂuenza incidence along the
eriod of the study. After checking for clustering by Autonomous
ommunity, we used a two level logistic regression model, intro-
ucing AC as random effect.23 We used STATA/IC 10 to carry out
he statistical analysis.
esults
andemic inﬂuenza (H1N1)2009 activity,
ay-October 2009, Spain
The Inﬂuenza 2008-9 season (from week 40/2008 to week
9/2009) was moderate, associated to a mixed circulation of
nﬂuenza A(H3N2) during the epidemic wave, and a further
redominant circulation of B virus.24 The number of sentinel physi-
ians participating in SISS increased from 525 GPs and 173 PDs in
eek 20/2009 to 647 GPs and 220 PDs in week 39/2009. The popu-
ation under surveillance increased with 22%, up to 2.53% in week
9/2009.
From week 20/2009 to week 25/2009 (ﬁrst weeks of the
xtended surveillance period), the inﬂuenza activity was low (ILI
ate below 12 cases/100,000). The ILI rate started to increase
teadily from week 26 (28 June – 4 July 2009), although inﬂuenza
ncidence rates maintained below baseline levels, overpassing it in
eek 38 (19-25 September 2009). Figure 1 shows the evolution of
eekly ILI ratesduring2008-9 season, during theusual surveillance
eriod (week 40/2008 to week 20/2009) and during the extended
urveillance period (May-September 2009).
From May to September 2009, the proportion of inﬂuenza sen-
inel positive specimens increased from 0 to 31%. From week 28,
his proportion was higher than 30% (ﬁg. 1).
The highest ILI rate was in the age group 5-14 years old (233
ases/100,000 population), followed by the 0-4 age group (153
ases/100,000 population) in week 39/2009.
The ﬁrst inﬂuenza pandemic (H1N1) 2009 virus was detected
n week 20, from a non-sentinel source. In week 23/2009 the sen-
inel systemdetected the ﬁrst (H1N1) 2009 conﬁrmed case. Among
he total inﬂuenza virus detected by the sentinel and non-sentinel
ources, the proportion of pandemic inﬂuenza (H1N1) 2009 was
4% in week 20/2009, 67% in week 21/2009 and more than 90%
rom week 34/2009.2008-2009 (weeks 40/08-19/09) influenza rate per 100,000
Baseline
sitive specimens in the sentinel system, 2008-2009 season, Spain.
In the study period, 3245 sentinel ILI cases were swabbed (3220
cases with age reported) representing 70% of total ILI medically
attended by sentinel GPs/PDs, ranging from 85% in 0-4 aged group
to 66% in over 64 years old (table 1). Out of 919 sentinel conﬁrmed
inﬂuenza, 92% were pandemic inﬂuenza (H1N1) 2009 (table 1).
Molecular characterization of the pandemic inﬂuenza
viruses detected by RT-PCR assays and subsenquentely
sequenced, showed that the circulating viruses were similar
to A/California/07/2009(H1N1) strain in both Nucleoprotein and
Haemagglutinine genes. Moreover, all pandemic viruses tested
were resistant to M2 inhibitors (Adamantanes) and none of them
showed mutation in the NA gene which conferred resistance to
neuraminidase inhibitors (oseltamivir).
Study of the effectiveness of inﬂuenza vaccine 2008-9
After the exclusion of inﬂuenza types B and C (n=24), no
subtyped inﬂuenza A cases (n =53), ILI patients with unknown vac-
cination status (n =148) or no age reported (n=25), we included in
the seasonal vaccine effectiveness study 2707 sentinel reported ILI
patients: 844 inﬂuenzapandemic (H1N1)2009 cases and1863 test-
negative ILI controls. Theweekly number of pandemic (H1N1) 2009
cases and test-negative controls increased by week of swabbing
(ﬁg. 2.
The cases were signiﬁcantly younger than controls (p<0.001):
mean age of cases: 20.8 years (standard deviation: 14.4), compared
with controls mean age: 25.1 years (standard deviation: 20.1). No
difference regarding genderwas registered between cases and con-
trols (p=0.202).
A total of 196 (7.24%) ILI patients included in the study were
vaccinated with the 2008-9 season trivalent vaccine: 42 (4.98%)
cases, and154 (8.27%) controls. The crudeORwas0.58 (95%CI: 0.39;
0.83). Stratifying by age group (table 1), we found no difference
between strata (homogeneity test p= .61) and a Mantel Haenzel
combined OR of 0.79 (IC 95%: 0.54; 1.16). The OR adjusted for sex,
age group, mounth of swabbing and Autonomous Community, was
0.88 (95%CI: 0.59; 1.30), resulting in an IVE of 12% (95% CI: -30; 41).Discussion
The Spanish inﬂuenza surveillance system proved its value
in an emergency situation, playing a critical role in monitor-
ing the inﬂuenza pandemic (H1N1) 2009 in Spain. Sentinel
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surveillance systems conﬁrmed to be a useful tool to monitor pan-
demic inﬂuenza in different countries and regions.10,25,26
For the ﬁrst time in 2009, Spain experienced a substantial
inﬂuenza activity during the summer, due to inﬂuenza pandemic
(H1N1) 2009 virus. Starting the end of June 2009, the proportion of
positive sentinel ILI cases and the proportion of pandemic (H1N1)
2009 viruses among all circulating inﬂuenza strains showed a sus-
tained circulation of inﬂuenza pandemic (H1N1) 2009 virus in all
Spanish ACs and in all age groups. In previous years, virological
surveillance conducted out of the usual inﬂuenza surveillance sea-
son, showed almost no inﬂuenza viral circulation.27
Following the surveillance recommendations, the proportion of
ILI patients swabbed in the sentinel system increased over 50%
comparing with the 2008-9 season.28 In order to cope with the
amount of specimens collected, the swabbing strategy changed
along the surveillance period (from all cases presenting to sen-
tinel physicians to a systematic swabbing, according to network
resources and laboratory capacity). The proportion of patients
tested was similar in all age groups showing that during summer
2009, swabbing was not inﬂuenced by the patient age as in previ-
ous inﬂuenza seasons,7 and reﬂected the distribution of inﬂuenza
vaccination coverage in Spain by age group.29
Similarities between pandemic (H1N1) 2009 virus and the sea-
sonal H1N1 one,30 might suggest that some effectiveness of the
seasonal vaccine 2008-9 which included a H1N1-like antigen for
the pandemic strain could be possible. A study in Australia did
not show any effect of the Southern hemisphere seasonal vaccine
2009 against medically attended laboratory conﬁrmed pandemic
inﬂuenza.10 In USA, the results of a study11 using the screening
method suggestednoeffectiveness of the trivalent seasonal vaccine
2008-9 against laboratory conﬁrmed pandemic inﬂuenza. In a hos-
pital case-controls study,12 the IVE of the seasonal vaccine 2008-9
against hospitalized pandemic inﬂuenza was estimated to be 73%
(95%CI: 34-89). However, it was argued that the reported protec-
tion might be due to a combination of selection bias and recall bias,
as the control group usedmight not represent the population given
rise to cases.31
Our results suggested that the seasonal vaccination 2008-9 did
not have any effect against the medically attended laboratory con-
ﬁrmed inﬂuenza pandemic (H1N1) 2009. The age groups most
affected by the inﬂuenza pandemic are not targeted by the sea-
sonal vaccination resulting in a low number of vaccinated in our
study population. In addition, we registered an important num-
ber of missings in the variable of exposure. Since no information
on other confounder factors known to inﬂuence the inﬂuenza vac-
cineeffectiveness (chronicdiseases, functional status, smoking, etc)
was collected in the routine surveillance system, we could only
adjust for sex, age, mounth of swabbing and autonomous commu-
nity. These limitations might inﬂuence the results of the inﬂuenza
vaccine effectiveness in both ways.
Controlling for the random effect of Autonomous Community
improved our model, even though the vaccine effectiveness point
estimate or conﬁdence interval did not change signiﬁcantly (data
not shown). This can be explained by the differences in the vaccina-
tion strategies, sentinel GP coverage and health seeking behaviour
among the Autonomous Communities.
In conclusion, the Spanish inﬂuenza surveillance system was
able to rapidly adapt to thenational and international requirements
for the surveillance of pandemic inﬂuenza (H1N1) 2009, becom-
ing an essential tool for pandemic monitoring in Spain. In order to
face this challenge, the number of sentinel physicians and popu-
lation covered by the system increased. In addition, a systematic
swabbing of ILI patients was introduced. These improvements in
the inﬂuenza surveillance system, if sustained, will help to better
monitor and provide more accurate information on the inﬂuenza
activity in the future seasonal or pandemic waves.
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Figure 2. A (H1N1) 2009 laboratory conﬁrmed cases and test-negative cont
Based on the inﬂuenza surveillance system, it was possible to
stimate the effectiveness of the seasonal vaccine 2008-9 against
andemic inﬂuenza (H1N1) 2009, showingno effect. Strengthening
he routine data collection by including data on the main con-
ounding factors will provide more accurate estimates of inﬂuenza
accine effectiveness. Since no effect of the seasonal vaccine was
xpected, vaccinationwithmonovalent pandemic vaccinewas rec-
mmended in Spain to prevent the pandemic inﬂuenza related
utcomes.32 The seasonal vaccination campaign started in Septem-
er 2009 and the pandemic vaccination campaign in November
009. In the next seasons, the surveillance system will continue
o be the basis to monitor inﬂuenza vaccine effectiveness.
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Appendix A.
SISS: Physicians of the inﬂuenza sentinel surveillance net-
worksof:Andalucía,Aragón,Asturias, Baleares, Canarias, Cantabria,
Castilla-La Mancha, Castilla y León, Catalun˜a, Comunidad Valen-
ciana, Extremadura,Madrid,Navarra, PaísVasco, LaRioja andCeuta.
Epidemiologists members of the SISS belonging to: Servicio de Vig-
ilancia Epidemiológica y Evaluación, Consejería de Salud, Junta de
Andalucía; Servicio de Vigilancia en Salud Pública, Dirección Gen-
eral de Salud Pública, Aragón; Dirección General de Salud Pública
y Planiﬁcación, Consejeria de Salud y Servicios Sanitarios, Asturias;
Servicio de Epidemiología, Dirección General de Salut Pública,
Baleares; Servicio de Epidemiología y Prevención, Consejería de
Sanidad de Canarias; Sección de Epidemiología, Consejería de
Sanidad, Trabajo y Servicios Sociales de Cantabria; Servicio de Epi-
demiología, ConsejeríadeSanidaddeCastilla-LaMancha;Dirección
General de Salud Pública e Investigación, Desarrollo e Innovación,
Consejería de Sanidad de Castilla y León; Servicio de Vigilan-
cia Epidemiológica, DGSP, Departament de Salut, Generalitat de
Catalunya; Àrea d’Epidemiologia, Conselleria de Sanitat, Comuni-
tat Valenciana; Servicio de Epidemiología, Consejería de Bienestar
Social, Junta de Extremadura; Dirección Xeral Saúde Pública de
Galicia; Dirección General de Atención Primaria de la Comu-
nidad de Madrid; Servicio de Epidemiología, Consejería de Sanidad
de la Región de Murcia; Sección de Vigilancia de Enfermedades
Transmisibles, Instituto de Salud Pública de Navarra; Servicio de
Vigilancia Epidemiológica, Consejería de Sanidad del País Vasco;
Servicio de Epidemiología, Subdirección de Salud Pública de La
Rioja; Sección de Vigilancia Epidemiológica, Consejería de Sanidad
y Bienestar Social de Ceuta; Centro Nacional de Epidemiología,
ISCIII, Madrid. Virologist members of the SISS belonging to labo-
ratories: National Inﬂuenza Reference Laboratory, WHO Inﬂuenza
colaborating Centre (Centro Nacional de Microbiología, ISCIII,
Madrid);WHO Inﬂuenza colaborating Centre, Facultad deMedicina
deValladolid;WHO Inﬂuenza collaboratingCentre,Hospital Clínico
de Barcelona; Hospital Virgen de las Nieves, Granada; Laborato-
rio del Hospital Miguel Servet, Zaragoza; Laboratorio del Hospital
Na Sra de Covadonga, Oviedo; Laboratorio del Hospital Son Dureta,
Palma de Mallorca; Laboratorio del Hospital Dr. Negrín, Las Palmas
de Gran Canaria; Laboratorio del Hospital Universitario Marqués
de Valdecilla, Santander; Instituto Valenciano de Microbiología,
Valencia; Hospital San Pedro de Alcántara, Cáceres; Servicio de
Microbiologia del Hospital Universitario Ramon y Cajal, Madird;
Laboratorio de la Clínica Universitaria deNavarra, Pamplona; Labo-
ratoriodeMicrobiología,HospitalDonostia, SanSebastián;Hospital
San Pedro de La Rioja, Logron˜o; Laboratorio de Microbiología del
2 c Sanit
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ospital de INGESA, Ceuta; Laboratorios de Microbioloxía CH de
igo y de Ourense Hospital Virgen de la Arrixaca, Murcia.
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